Combination therapy for untreated advanced head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of three drugs (cetuximab, tislelizumab, and chemotherapy) in people with advanced head and neck cancer that hasn't been treated before. The goal is to see if this mix can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with head and neck cancer that is locally advanced and cannot be completely removed by surgery.
- You have not had any prior treatment for this cancer (like chemo, radiation, or immunotherapy).
- You are generally in good health, able to care for yourself, and at least 18 years old.
- Your kidney, liver, and blood cell counts are within a certain healthy range.
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests adding a targeted therapy (cetuximab) to an immunotherapy (pembrolizumab or finotonlimab) plus chemotherapy for people with head and neck cancer that has spread or come back. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
This trial tests whether adding an immunotherapy drug (toripalimab) with or without another targeted drug (cetuximab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck squamous cell carcinoma that can be removed with surgery.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
Hear when a new LA HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.